ESC 365 - The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

ACVC Premium Access

The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

Session: Live Abstract session - Antithrombotics and bleeding

Topic: Antiplatelet Drugs

Speaker: Doctor H. Wang (Beijing, CN)

Event: ACVC 2021

Congress Presentation

Add to my library

About the speaker

Doctor Haoyu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

0 follower

7 more presentations in this session

Trends in major bleeding events in patients with acute coronary syndrome.

Speaker: Doctor A. Cordero (Elche, ES)

Long-term ischemic and bleeding risk with extended dual antiplatelet therapy after PCI in patients with 2018 ESC/EACTS myocardial revascularization guideline-endorsed high thrombotic risk features.

Speaker: Doctor H. Wang (Beijing, CN)

Safety and efficacy of direct oral anticoagulants (DOACs) vs warfarin in patients with concurrent atrial fibrillation and bioprosthetic mitral or aortic valve replacement-a meta analysis

Speaker: Ms A. Abdul Razzack (Vijayawada, IN)

Cardiovascular outcomes of clopidogrel and aspirin vs ticagrelor and aspirin in geriatric population with acute coronary syndrome-a systematic review and meta analysis

Speaker: Ms A. Abdul Razzack (Vijayawada, IN)

Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome

Speaker: Doctor H. Wang (Beijing, CN)

Access the full session

Live Abstract session - Antithrombotics and bleeding

Speakers: Doctor H. Wang, Doctor A. Cordero, Doctor H. Wang, Ms A. Abdul Razzack, Ms A. Abdul Razzack...

About the event

ACVC 2021

13 March - 14 March 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources